Dermatitis herpetiformis: Part II. Diagnosis, management, and prognosis

Journal of the American Academy of Dermatology

Volumn 64, Issue 6, 2011, Pages 1027-1033

  Bolotin, Diana ^a   Petronic Rosic, Vesna ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

autoimmune bullous disease; celiac disease; dapsone; dermatitis herpetiformis; enzyme linked immunosorbent assay; gliadin; gluten free diet; gluten sensitive enteropathy; human leukocyte antigen DQ2; human leukocyte antigen DQ8; immunofluorescence; immunoglobulin A; sulfapyridine

Indexed keywords

CORTICOSTEROID DERIVATIVE; DAPSONE; SALAZOSULFAPYRIDINE; SULFAMETHOXYPYRIDINE; SULFAPYRIDINE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; CLINICAL TRIAL; DERMATITIS HERPETIFORMIS; FOLLOW UP; GENETIC ANALYSIS; GLUTEN FREE DIET; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; METHEMOGLOBINEMIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PUNCH BIOPSY; REVIEW; SEROLOGY;

ANTI-INFECTIVE AGENTS; DAPSONE; DERMATITIS HERPETIFORMIS; DIET, GLUTEN-FREE; HUMANS; PATIENT CARE TEAM; PHYSICAL EXAMINATION; PROGNOSIS; SEROLOGIC TESTS; TREATMENT OUTCOME;

EID: 79956126241     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.09.776     Document Type: Review

References (50)

1. Caproni M, Antiga E, Melani L, Fabbri P. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. J Eur Acad Dermatol Venereol 2009;23:633-8.
2. Lever WF, Elder DE, editors. Lever's histopathology of the skin. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009.
3. Zone JJ, Meyer LJ, Petersen MJ. Deposition of granular IgA relative to clinical lesions in dermatitis herpetiformis. Arch Dermatol 1996;132:912-8. (Pubitemid 26266933)
4. Zone JJ, Egan CA, Taylor TB, Meyer LJ. IgA autoimmune disorders: development of a passive transfer mouse model. J Investig Dermatol Symp Proc 2004;9:47-51. (Pubitemid 38096198)
5. Dieterich W, Laag E, Bruckner-Tuderman L, Reunala T, Karpati S, Zagoni T, et al. Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol 1999;113:133-6. (Pubitemid 29328172)
6. Beutner EH, Chorzelski TP, Reunala TL, Kumar V. Immunopathology of dermatitis herpetiformis. Clin Dermatol 1991;9: 295-311.
7. Rose C, Dieterich W, Brocker EB, Schuppan D, Zillikens D. Circulating autoantibodies to tissue transglutaminase differentiate patients with dermatitis herpetiformis from those with linear IgA disease. J Am Acad Dermatol 1999;41:957-61.
8. Jaskowski TD, Hamblin T, Wilson AR, Hill HR, Book LS, Meyer LJ, et al. IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis and pediatric celiac disease. J Invest Dermatol 2009;129:2728-30.
9. Rose C, Armbruster FP, Ruppert J, Igl BW, Zillikens D, Shimanovich I. Autoantibodies against epidermal transglutaminase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet. J Am Acad Dermatol 2009;61:39-43.
10. Marietta EV, Camilleri MJ, Castro LA, Krause PK, Pittelkow MR, Murray JA. Transglutaminase autoantibodies in dermatitis herpetiformis and celiac sprue. J Invest Dermatol 2008;128: 332-5.
11. Kumar V, Jarzabek-Chorzelska M, Sulej J, Karnewska K, Farrell T, Jablonska S. Celiac disease and immunoglobulin a deficiency: how effective are the serological methods of diagnosis? Clin Diagn Lab Immunol 2002;9:1295-300.
12. Samolitis NJ, Hull CM, Leiferman KM, Zone JJ. Dermatitis herpetiformis and partial IgA deficiency. J Am Acad Dermatol 2006;54(5 suppl):S206-9.
13. Zone JJ. Skin manifestations of celiac disease. Gastroenterology 2005;128(4 suppl. 1):S87-91.
14. Karpati S. Dermatitis herpetiformis: close to unravelling a disease. J Dermatol Sci 2004;34:83-90. (Pubitemid 38368946)
15. Loviselli A, Velluzzi F, Mossa P, Cambosu MA, Secci G, Atzeni F, et al. The Sardinian Autoimmunity Study: 3. Studies on circulating antithyroid antibodies in Sardinian schoolchildren: relationship to goiter prevalence and thyroid function. Thyroid 2001;11:849-57.
16. Di Sabatino A, Rosado MM, Cazzola P, Riboni R, Biagi F, Carsetti R, et al. Splenic hypofunction and the spectrum of autoimmune and malignant complications in celiac disease. Clin Gastroenterol Hepatol 2006;4:179-86. (Pubitemid 43199688)
17. Di Sabatino A, Rosado MM, Miele L, Capolunghi F, Cazzola P, Biancheri P, et al. Impairment of splenic IgM-memory but not switched-memory B cells in a patient with celiac disease and splenic atrophy. J Allergy Clin Immunol 2007;120:1461-3. (Pubitemid 350216592)
18. Collin P, Reunala T. Recognition and management of the cutaneous manifestations of celiac disease: a guide for dermatologists. Am J Clin Dermatol 2003;4:13-20. (Pubitemid 36078536)
19. Garioch JJ, Lewis HM, Sargent SA, Leonard JN, Fry L. 25 years' experience of a gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol 1994;131:541-5. (Pubitemid 24315424)
20. Fry L, Leonard JN, Swain F, Tucker WF, Haffenden G, Ring N, et al. Long term follow-up of dermatitis herpetiformis with and without dietary gluten withdrawal. Br J Dermatol 1982; 107:631-40. (Pubitemid 13238859)
21. Fry L, McMinn RM, Cowan JD, Hoffbrand AV. Gluten-free diet and reintroduction of gluten in dermatitis herpetiformis. Arch Dermatol 1969;100:129-35.
22. Kilander AF, Gillberg RE, Kastrup W, Mobacken H, Nilsson LA. Serum antibodies to gliadin and small-intestinal morphology in dermatitis herpetiformis. A controlled clinical study of the effect of treatment with a gluten-free diet. Scand J Gastroenterol 1985;20:951-8. (Pubitemid 16236019)
23. Fry L, Seah PP, Riches DJ, Hoffbrand AV. Clearance of skin lesions in dermatitis herpetiformis after gluten withdrawal. Lancet 1973;1:288-91.
24. Reunala T, Blomqvist K, Tarpila S, Halme H, Kangas K. Glutenfree diet in dermatitis herpetiformis. I. Clinical response of skin lesions in 81 patients. Br J Dermatol 1977;97:473-80.
25. Schalock PC, Baughman RD. Flare of dermatitis herpetiformis associated with gluten in multivitamins. J Am Acad Dermatol 2005;52:367.
26. Parnell N, Ellis HJ, Ciclitira P. Absence of toxicity of oats in patients with dermatitis herpetiformis. N Engl J Med 1998;338: 1470-1. (Pubitemid 28221994)
27. Hardman CM, Garioch JJ, Leonard JN, Thomas HJ, Walker MM, Lortan JE, et al. Absence of toxicity of oats in patients with dermatitis herpetiformis. N Engl J Med 1997;337: 1884-7. (Pubitemid 28053028)
28. Hardman C, Fry L, Tatham A, Thomas HJ. Absence of toxicity of avenin in patients with dermatitis herpetiformis. N Engl J Med 1999;340:321. (Pubitemid 29063282)
29. Reunala T, Collin P, Holm K, Pikkarainen P, Miettinen A, Vuolteenaho N, et al. Tolerance to oats in dermatitis herpetiformis. Gut 1998;43:490-3. (Pubitemid 28462033)
30. Rashid M, Butzner D, Burrows V, Zarkadas M, Case S, Molloy M, et al. Consumption of pure oats by individuals with celiac disease: a position statement by the Canadian Celiac Association. Can J Gastroenterol 2007;21:649-51. (Pubitemid 350200500)
31. Lewis HM, Renaula TL, Garioch JJ, Leonard JN, Fry JS, Collin P, et al. Protective effect of gluten-free diet against development of lymphoma in dermatitis herpetiformis. Br J Dermatol 1996; 135:363-7. (Pubitemid 26297828)
32. Leonard JN, Fry L. Treatment and management of dermatitis herpetiformis. Clin Dermatol 1991;9:403-8.
33. Egan CA, O'Loughlin S, Gormally S, Powell FC. Dermatitis herpetiformis: a review of fifty-four patients. Ir J Med Sci 1997; 166:241-4. (Pubitemid 27500869)
34. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001;45:420-34. (Pubitemid 32800500)
35. Booth SA, Moody CE, Dahl MV, Herron MJ, Nelson RD. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992;98:135-40.
36. Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 1997;62:827-36. (Pubitemid 28015631)
37. Martin WJ 2nd, Kachel DL. Reduction of neutrophil-mediated injury to pulmonary endothelial cells by dapsone. Am Rev Respir Dis 1985;131:544-7. (Pubitemid 15086737)
38. Thuong-Nguyen V, Kadunce DP, Hendrix JD, Gammon WR, Zone JJ. Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Invest Dermatol 1993;100: 349-55. (Pubitemid 23105195)
39. Wolverton SE. Comprehensive dermatologic drug therapy. Philadelphia: Saunders Elsevier; 2007.
40. Nicolas ME, Krause PK, Gibson LE, Murray JA. Dermatitis herpetiformis. Int J Dermatol 2003;42:588-600. (Pubitemid 37025207)
41. Willsteed E, Lee M, Wong LC, Cooper A. Sulfasalazine and dermatitis herpetiformis. Australas J Dermatol 2005;46:101-3. (Pubitemid 40704888)
42. Goldstein BG, Smith JG Jr. Sulfasalazine in dermatitis herpetiformis. J Am Acad Dermatol 1990;22:697. (Pubitemid 20134724)
43. McFadden JP, Leonard JN, Powles AV, Rutman AJ, Fry L. Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid. Br J Dermatol 1989; 121:759-62. (Pubitemid 20014857)
44. Shah SA, Ormerod AD. Dermatitis herpetiformis effectively treated with heparin, tetracycline and nicotinamide. Clin Exp Dermatol 2000;25:204-5. (Pubitemid 30340547)
45. Alexander JO. The treatment of dermatitis herpetiformis with heparin. Br J Dermatol 1963;75:289-93.
46. Stenveld HJ, Starink TM, van Joost T, Stoof TJ. Efficacy of cyclosporine in two patients with dermatitis herpetiformis resistant to conventional therapy. J Am Acad Dermatol 1993; 28:1014-5. (Pubitemid 23160660)
47. Johnson HH Jr, Binkley GW. Nicotinic acid therapy of dermatitis herpetiformis. J Invest Dermatol 1950;14:233-8.
48. Zemtsov A, Neldner KH. Successful treatment of dermatitis herpetiformis with tetracycline and nicotinamide in a patient unable to tolerate dapsone. JAmAcad Dermatol 1993;28:505-6. (Pubitemid 23075278)
49. Silvers DN, Juhlin EA, Berczeller PH, McSorley J. Treatment of dermatitis herpetiformis with colchicine. Arch Dermatol 1980; 116:1373-84.
50. Collin P, Pukkala E, Reunala T. Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease. Gut 1996;38:528-30. (Pubitemid 26111372)